AbbVie CSO calls its DMT-related bretisilocin a breakthrough type therapy as J&J Spravato sales keep surging

DMT-related bretisilocin is framed by AbbVie as a "breakthrough type therapy" for major depressive disorder, with AbbVie Chief Scientific Officer Roopal Thakkar emphasizing a short hallucinatory period that dissipates quickly so patients can leave the clinic sooner. The article links that positioning to Gilgamesh Pharmaceuticals selling bretisilocin to AbbVie for $1.2 billion and points to earlier Phase 2 results reported in March 2025, where nearly all treated patients with MDD reached disease remission. It also connects AbbVie momentum to Johnson & Johnsons established esketamine-based Spravato growth, citing sharp sales gains in the fourth quarter and annual revenue growth. The growing Spravato market is presented as evidence that psychedelics can generate meaningful sales in hard-to-treat CNS conditions, potentially paving the way for other psychedelics in development.